News Briefs

✦ Herzuma (trastuzumab-pkrb) launched on March 16, bringing the total number of Herceptin (trastuzumab) biosimilars to four. Herzuma, from Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and Celltrion Healthcare Co., Ltd., is approved for all the indications of its reference product, which is from Genentech USA, Inc., a Roche Group company. Herzuma’s wholesale acquisition cost for a 150 mg vial is $1,402.50, while a 420 mg vial is $3,927, both 10% less than Herceptin’s WAC. Visit www.herzuma.com.

✦ Prime Therapeutics LLC launched its PreserveRx gene therapy reinsurance solution on April 6. The company is working with BCS Insurance Co., a subsidiary of BCS Financial Corp., on the product, which will give Blues plans financial protection for five gene therapies: the already-available $850,000 per person one-time therapy Luxturna (voretigene neparvovec-rzyl) and $2.1 million PP one-time therapy Zolgensma (onasemnogene abeparvovec-xioi), as well as valoctocogene roxaparvovec (valrox), LentiGlobin and GT-AADC, three products expected to gain FDA approval this year. PreserveRx also has a clinical services component that will help forecast the products’ financial impact and potential use and ensure appropriate utilization. Contact Jenine Anderson at Jenine.Anderson@primetherapeutics.com.

0

0

0 Comments

0

0

• Radar on Specialty Pharmacy